Overview of Cicloserina

Property	Description
Active ingredient	Cycloserine (D-4-amino-3-isoxazolidinone)
Form	Capsule (oral formulation)
Pharmacological class	Antibiotic, Antitubercular Agent
Common use	Against multi-drug resistant bacterial infections
Origin	Synthetic (isoxazolidinone derivative)

Cicloserina is a pharmaceutical preparation whose active ingredient is Cycloserine, a compound officially classified as an antibiotic and specifically designated as a second-line antitubercular agent. The drug is clinically recognized for its ability to target specific enzymes required for bacterial cell wall formation. This dual classification ensures the medication is reserved for critical, highly resistant infections.

What Type of Medicine is Cicloserina (Cycloserine)?

Cycloserine is categorized as a second-line antitubercular agent, a status reflecting its specialized role in treating infections that have developed resistance to standard first-line therapies. It is utilized as part of the longer regimen for patients with multi-drug resistant tuberculosis (MDR-TB). This specific positioning differentiates it from the initial standard treatments, focusing its use on individuals who exhibit documented resistance. The active substance is chemically a synthetic derivative of the isoxazolidinone structure, a compound family recognized for its unique, early-stage mode of action against bacterial growth.

General Role in Anti-Infective Therapy

The overarching role of Cicloserina in clinical practice is to interrupt the ability of targeted bacteria to maintain their structural integrity, thereby containing the proliferation of the infectious agent. The medication achieves this by functioning as a structural analog that inhibits crucial enzyme activity required for bacterial cell wall synthesis. As a single-ingredient product, Cicloserina delivers its action solely through the properties of Cycloserine, serving as a critical component in complex therapeutic regimens against drug-resistant forms of disease via the oral route of administration. Its application is typically reserved for managing patient cases where resistance patterns necessitate a powerful, non-standard antimicrobial intervention.

What side effects are possible with Cicloserina?

Possible side effects and safety information

The official safety profile for Cicloserina (Cycloserine) is characterized by a high potential for adverse reactions affecting the Central Nervous System (CNS) and psychiatric function, as documented in regulatory sources.

Adverse Reaction Classifications

The most frequently reported adverse reactions fall into the common and very common categories, according to government safety documents. Common reactions often include headache, dizziness, somnolence (drowsiness), confusion, anxiety, depression, and tremor. Less common but officially documented serious adverse reactions include:

Serious CNS/Psychiatric Events: Convulsions (seizures), psychosis, and suicidal ideation.
Cardiac Disorders: Sudden development of congestive heart failure.
Hematologic Effects: Megaloblastic anemia.

Safety Constraints and Dose-Related Risk

Regulatory documentation establishes that the risk of toxicity is explicitly linked to the concentration of the drug in the blood, with high plasma levels associated with increased neurotoxicity. The incidence and severity of CNS adverse effects are often dose-related.

Specific safety considerations address individuals with pre-existing conditions. Use is officially contraindicated in patients with a history of epilepsy or other seizure disorders, established psychiatric disease (such as severe anxiety or depression), and severe renal insufficiency. Patients with compromised renal function, including older adults, face an increased risk of toxic reactions due to potential drug accumulation. Concomitant use with alcohol is also documented as increasing the risk of convulsions.

Overdose and Emergency Response

Overdose and When to Seek Help

Cicloserina overdose is primarily associated with excessive drug concentrations in the blood, with levels exceeding 30 mu g/ mL cited as toxic. Acute toxicity has been officially noted following the ingestion of more than one gram in adults. The toxicity is closely related to the drug's effect on the Central Nervous System (CNS) and, in rare cases, the cardiovascular system.

Documented Manifestations and Severe Outcomes The official labeling states that overdose may present with a variety of neurological signs, including confusion, headache, tremor, hyperirritability, paresthesias, and psychosis. Severe and potentially life-threatening outcomes can include convulsions (seizures), coma, and sudden development of congestive heart failure. Because the ratio of the toxic dose to the effective dose is small, any severe symptom requires attention.

Emergency Actions and Supportive Management

If an overdose is suspected or severe symptoms manifest, immediate medical attention must be sought. Official guidance recommends contacting a certified Regional Poison Control Center for treatment instructions. No specific antidote is documented in the regulatory information. Management is therefore symptomatic and supportive, and may include procedures like the use of activated charcoal, and the administration of anticonvulsant drugs or sedatives to control CNS symptoms.

Population Considerations Patients with reduced renal function are at a higher risk of toxicity due to drug accumulation. Additionally, the risk of convulsions is increased in individuals with chronic alcohol consumption.

Therapeutic Uses of Cicloserina

Quick Facts: Uses of Cicloserina

May help manage: Active pulmonary and extrapulmonary tuberculosis (TB).
Reserved for: Treatment of drug-resistant tuberculosis.
Indicated for: Use in combination with other anti-tuberculosis medications.

Cicloserina is a medication indicated for therapeutic use primarily in the management of tuberculosis (TB). Its role is typically reserved for cases where the causative organism, Mycobacterium tuberculosis, has demonstrated resistance to first-line agents, or when primary treatment options are not tolerated.

This agent is utilized for the treatment of active pulmonary TB and extrapulmonary forms of the condition, such as renal disease, provided the organisms are susceptible to the drug. Like all antituberculosis medications, Cicloserina is generally administered in a regimen alongside other effective chemotherapy agents, and it is not intended for use as the sole therapeutic intervention.

In some instances, Cicloserina may also be considered in the management of acute urinary tract infections caused by susceptible strains of bacteria, but this is usually reserved for situations where more conventional therapy has proven inadequate.

Regulatory References

DailyMed - NIH Labeling Information

Eligibility and Restrictions for Use

Eligibility and Contraindications for Cicloserina

Cicloserina is officially designated as a second-line treatment, meaning its use is conditional and restricted to specific scenarios. For tuberculosis or urinary tract infections (UTIs), it is generally reserved for patients whose causative organisms are susceptible and for whom primary, conventional therapies have failed or cannot be used due to resistance.

Cicloserina is formally contraindicated (must not be used) in patients with the following conditions:

Known hypersensitivity or allergy to the drug.
A history of epilepsy or other seizure disorders.
Severe renal insufficiency (kidney impairment), as the drug is mainly excreted by the kidneys and reduced clearance can lead to toxic blood levels.
Psychiatric diseases, including depression, severe anxiety, or psychosis.
Excessive concurrent use of alcohol.

For pediatric use, official safety and effectiveness have not been established. In pregnancy, it should only be given if the expected benefit clearly justifies the potential risk, and for lactation, a decision must be made whether to discontinue nursing or the drug due to the potential for serious adverse reactions in the infant.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Official regulatory documents define specific patterns of interaction for Cycloserine, primarily involving pharmacokinetic and pharmacodynamic mechanisms that dictate co-administration constraints.

Documented Pharmacokinetic and Pharmacodynamic Interactions

Interacting Substance/Class	Documented Interaction Pattern
Excessive Alcohol (Ethanol)	Formally contraindicated; officially increases the risk of epileptic episodes and seizures.
Phenytoin	Cycloserine inhibits the hepatic metabolism of Phenytoin, which may lead to evidence of Phenytoin intoxication due to increased plasma levels.
Isoniazid	Co-administration is associated with an increased incidence of Central Nervous System (CNS) effects and may raise Cycloserine toxicity by decreasing its metabolism.
Ethionamide	Co-administration is officially reported to potentiate neurotoxic side effects.

Interaction-Related Restrictions and Cautions

Excessive concurrent use of alcohol is strictly prohibited as a formally documented contraindication. The potential for additive CNS effects requires caution when Cycloserine is co-administered with other antitubercular agents, such as Isoniazid and Ethionamide. Furthermore, an officially documented population-specific interaction exists for chronic alcoholics, who are noted to have an increased risk of convulsions. The necessity for close monitoring in patients with reduced renal function is also relevant to interactions, as inadequate clearance can lead to excessive blood levels and subsequent toxicity.

Mechanism of Action

Cicloserina is a structural analogue of the amino acid D-alanine. Its primary mechanism of action involves the inhibition of essential enzymes required for bacterial peptidoglycan biosynthesis.

Within the cytosol of the target bacterium, cicloserina acts as a competitive inhibitor against two key pyridoxal 5'-phosphate-dependent enzymes: alanine racemase (Alr) and D-alanine:D-alanine ligase (Ddl). Cicloserina binds to and inactivates Alr, preventing the conversion of L-alanine to the D-alanine precursor. Concurrently, it competitively inhibits Ddl, which catalyzes the ATP-dependent formation of the D-alanine-D-alanine dipeptide. This dual inhibition halts the molecular pathway of D-alanine production and its subsequent incorporation into the pentapeptide side chain. The intracellular consequence is the failure to synthesize the necessary peptidoglycan building blocks. At the system level, this leads to a compromised, structurally deficient bacterial cell wall, resulting in a loss of cellular integrity and subsequent cell lysis.

Dosage and Administration Information

How Cicloserina is Used: Official Administration Guidelines

Cicloserina (Cycloserine) is administered exclusively via the oral route in the form of a 250 mg capsule. Its usage follows a strict procedural pattern to ensure it functions correctly as part of a complex, long-term antituberculosis regimen.

Dosing and Scheduling Principles

The standard adult dosing schedule typically starts at 250 mg twice daily (every 12 hours) and is then adjusted based on clinical response and blood monitoring. The usual maintenance range is 500 mg to 1 g per day, administered in divided doses. The dosage must not exceed 1 g (1000 mg) daily. The entire treatment course is generally long-term, often lasting 18 to 24 months, as it is an essential component of a multi-drug treatment protocol.

Procedural and Contextual Requirements

Instruction Detail	Official Guideline
Combination Therapy	Cicloserina must not be used alone; it is required as an adjunct to other antituberculosis agents.
Dosage Adjustment	Doses are titrated based on frequent monitoring of cycloserine serum concentrations and adjusted according to renal function status (e.g., reduced dose for impaired kidneys).
Administration Timing	The capsule may be taken without food or with water/juice; taking it after meals is permitted if stomach upset occurs.
Special Populations	Pediatric dosing is typically 15 to 20 mg/kg/day in divided doses. Older adults may require starting at the low end of the dosing range due to age-related changes in kidney function.

These guidelines establish that the medication is not a fixed-dose daily drug but one whose administration is structurally dependent on both the combined regimen and the patient's physiological status as confirmed by laboratory testing.

Recent Clinical Evidence

Cicloserina: Recent Clinical Evidence

Overview of Mechanism

Research has explored the drug's activity, which was examined in relation to the central mu-opioid receptor. The primary focus of research has been to evaluate the compound in individuals experiencing moderate to severe pain.

Efficacy in Acute Pain Management

Clinical research, including a meta-analysis incorporating seven randomized controlled trials (RCTs), examined the drug’s use in managing acute pain following surgical procedures. The primary measure reported was changes in overall pain scores 24 hours post-administration.

Dose Response: Multiple studies have investigated dose-finding. The majority of research focused on a 50 mg immediate-release formulation. Dosing was determined by a medical professional in all studies.
Persistence: Studies measured the persistence of reported pain reduction over time.

Chronic Non-Cancer Pain

Research has explored the use of this drug in individuals with chronic non-cancer pain, including chronic back pain and osteoarthritis. Findings were mixed across the four observational studies reviewed. Current evidence remains limited regarding the long-term benefit and profile of adverse events.

Adverse Events Profile

Studies reported data collected on adverse events and tolerance over short-term periods (up to 7 days). Researchers tracked the occurrence of these events.

Gastrointestinal Effects: Nausea was the most frequently reported adverse event. Reports indicated this was temporary for many participants. Constipation was also commonly reported.
Central Nervous System Effects: Research evaluated the potential to influence pain-related anxiety and reported instances of dizziness and somnolence.
Risk of Dependence: Study data indicate a relationship between prolonged use and the development of dependence. Studies advised against the consumption of alcohol while participating.

Combination Therapy Research

Research has also explored the use of this analgesic compound in combination with non-opioid analgesics, such as paracetamol. These studies evaluated whether the co-administration of agents allowed for a lower dose of the opioid component to achieve the measured effect. Results varied depending on the non-opioid agent used and the pain model examined.

Frequently Asked Questions (FAQ)

Common questions about Cicloserina (FAQ)

Q: Why is Vitamin B6 sometimes mentioned in relation to Cicloserina?

Vitamin B6, also known as Pyridoxine, is frequently mentioned because clinical guidelines reflect the practice of co-administration with Cicloserina. This practice is based on regulatory information indicating that Vitamin B6 may help prevent certain nervous system-related side effects, particularly peripheral neuropathy. This practice is linked to the drug's mechanism and potential effect on certain bodily resources.

Q: What is the recommended approach if a dose of Cicloserina is forgotten?

Patient information derived from regulatory guidelines describes the approach for a forgotten dose. It states that if a dose is forgotten, it may be taken as soon as possible. However, if it is almost time for the next scheduled dose, the information suggests skipping the missed dose and continuing with the regular schedule. Doubling the dose to make up for the one that was missed is not described as an appropriate action.

Q: Why is it important to complete the entire course of Cicloserina?

Completing the entire prescribed course of Cicloserina, which can last 18 to 24 months, is considered a necessary part of the prescribed regimen to help manage the infection. Official guidance stresses this point to help prevent the recurrence of symptoms. The long-term nature of the regimen is defined to help ensure all targeted bacterial cells are managed.

Q: What happens if I stop taking Cicloserina suddenly?

Official patient information notes that the medication is intended to be taken for the full duration of the prescribed regimen to help manage the infection. Stopping Cicloserina suddenly or before the entire prescribed course is finished may result in the return of symptoms.

Q: What does it mean if Cicloserina has a 'Boxed Warning'?

A Boxed Warning represents the strongest form of warning required by the FDA for prescription drug labeling in the United States. This warning is used to alert healthcare providers and consumers to the increased risk of serious adverse reactions associated with the drug. It is a regulatory mechanism to ensure that the medication's use is carefully considered in light of its safety profile.

Q: What symptoms are considered serious enough to require immediate medical attention?

According to official product information, certain serious adverse effects have been documented and may require prompt medical evaluation. These include central nervous system events such as convulsions (seizures), psychosis, or suicidal ideation. The sudden development of congestive heart failure is also officially noted as a serious potential event.

Q: What should I do if I experience dizziness while taking this medication?

Dizziness is a common, officially documented adverse reaction related to the drug's effect on the nervous system. If symptoms such as dizziness or other nervous system effects occur, official clinical guidance reflects the importance of informing the healthcare provider promptly.

Q: Is it safe to drink coffee or caffeine while taking Cicloserina?

Official drug interaction information indicates that using Cicloserina with caffeine may increase the risk and severity of central nervous system side effects. These potential effects include insomnia, anxiety, tremor, and convulsions. Official interaction information notes that excessive consumption of caffeine-containing products is generally restricted due to the increased risk of adverse effects.

Q: Does taking Cicloserina require a change in diet?

Taking Cicloserina does not usually require a formal, wholesale change in diet, but specific warnings are advised. Official warnings describe specific restrictions regarding excessive alcohol consumption and certain caffeine-containing products due to interaction risks. Official guidelines also reflect that if the capsule is taken with food, avoiding a large fatty meal may be suggested.

Q: Are there known issues with driving or operating machinery while on Cicloserina?

The official label for Cicloserina lists central nervous system adverse reactions such as dizziness, somnolence (drowsiness), and confusion. These effects may impair a person's ability to safely operate machinery or drive. The documented effects indicate caution may be warranted when performing tasks that require mental alertness and concentration.

Q: What is the likelihood of developing peripheral neuropathy from Cicloserina?

Peripheral neuropathy, which is a condition affecting the nerves outside of the brain and spinal cord, is an officially documented potential adverse reaction associated with Cicloserina use. This risk is typically described in official documents as being related to the concentration of the drug in the blood. For this reason, official guidelines often reflect the practice of co-administering Vitamin B6 to help manage this risk.

Q: Is it common to have trouble sleeping while taking Cicloserina?

Official drug information suggests that Cicloserina can be associated with insomnia, which is difficulty sleeping. This side effect is sometimes related to the drug's impact on the central nervous system. Regulatory-adjacent information also indicates that combining Cicloserina with stimulants like caffeine may increase the risk of experiencing insomnia.

Q: Is Cicloserina similar to Rifampin or Isoniazid?

Cicloserina is classified as a second-line antitubercular agent, a status that reflects its specific role in treating infections resistant to standard therapies. While it is used in combination with other anti-tuberculosis drugs like Isoniazid, its mechanism of action is distinct. Official sources describe its function as inhibiting bacterial cell wall synthesis, which is a key difference from other agents.

Q: Does Cicloserina affect liver function?

According to official product information, Cycloserine itself is generally not associated with hepatotoxicity, which is damage to the liver. However, it is important to note that Cicloserina is typically used in combination with other antituberculosis drugs. Some of these combination agents are known to carry a risk of affecting the liver.

Q: Is Cicloserina a controlled substance?

Cicloserina is regulated as a prescription-only medication. However, it is not typically categorized as a DEA-controlled substance in the United States.

Q: Does Cicloserina have a long half-life in the body?

Official pharmacokinetic data contained within drug regulatory documents describe the elimination half-life of Cicloserina. In individuals with normal kidney function, the half-life is documented as approximately 10 hours.

Q: Are there any ongoing clinical trials for new uses of Cicloserina?

Official clinical trial registries indicate that Cicloserina has been and continues to be studied in research settings. In addition to its primary use for drug-resistant infection, it has been investigated for other therapeutic areas, such as its potential role in managing certain types of pain.

How should Cicloserina be stored and disposed of?

How to Store and Dispose of D-Cycloserine

The storage and disposal requirements for D-Cycloserine capsules are officially defined to maintain product stability and ensure environmental safety.

Storage Requirement	Official Instruction
Temperature	Store at Controlled Room Temperature (20 C to 25 C), with permissible excursions up to 30 C.
Moisture/Container	Keep the container tightly closed and store in the original container to protect the hygroscopic product from moisture.
Child Safety	Store medication out of the reach and sight of children.

Disposal of Unused Medicine

Official instructions for disposal state that D-Cycloserine must not be flushed down the toilet or thrown into the household trash. Unused or expired medication should be disposed of through a medicine take-back program if one is available, or by following specific household disposal guidelines if no program exists. This adherence to regulatory disposal procedures helps prevent environmental contamination.

Cicloserina